Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

Clinical trial NCT05104723 · COMPLETED

Trial details

NCT number: NCT05104723
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Chronic Granulomatous Disease Inflammatory Gastrointestinal Disease Inflammatory Skin Disease Inflammatory Lung Disease

Start date: 2022-08-12
Primary completion: 2026-05-04
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.